1. Home
  2. ZENV vs RFL Comparison

ZENV vs RFL Comparison

Compare ZENV & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zenvia Inc.

ZENV

Zenvia Inc.

HOLD

Current Price

$0.99

Market Cap

58.9M

Sector

Technology

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.17

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZENV
RFL
Founded
2005
2017
Country
Brazil
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Real Estate
Sector
Technology
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
58.9M
54.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ZENV
RFL
Price
$0.99
$1.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.0K
188.7K
Earning Date
03-16-2026
12-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$201,426,369.00
$1,029,000.00
Revenue This Year
$12.75
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.80
47.63
52 Week Low
$0.94
$1.15
52 Week High
$3.03
$3.19

Technical Indicators

Market Signals
Indicator
ZENV
RFL
Relative Strength Index (RSI) 33.45 40.12
Support Level $1.05 $1.21
Resistance Level $1.13 $1.29
Average True Range (ATR) 0.09 0.11
MACD -0.02 -0.01
Stochastic Oscillator 24.30 4.44

Price Performance

Historical Comparison
ZENV
RFL

About ZENV Zenvia Inc.

Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: